Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.
Alexander GrunenbergElisa SalaSilke Kapp-SchwoererAndreas ViardotPublished in: Expert opinion on pharmacotherapy (2022)
Intensifying chemotherapy may reduce the incidence of recurrent disease in adult patients, but it has not come without a cost. Novel agents with selective T-ALL activity (e.g. nelarabine) may improve survival in some patient subsets. Due to modern genomic and transcriptomic techniques, various novel potential targets might change the treatment landscape in the next few years and will, hopefully alongside with cellular therapies, augment the therapeutic armamentarium in the near future.
Keyphrases
- acute lymphoblastic leukemia
- single cell
- systematic review
- risk factors
- case report
- allogeneic hematopoietic stem cell transplantation
- current status
- peripheral blood
- rna seq
- gene expression
- squamous cell carcinoma
- locally advanced
- radiation therapy
- acute myeloid leukemia
- replacement therapy
- dna methylation
- climate change
- risk assessment
- smoking cessation
- chemotherapy induced